The approaches to diagnostic and treatment of anxiety and depressive disorders in oncological patients


Cite item

Full Text

Abstract

The malignant neoplasms are quite often combined with psychic disorders of depressive and anxiety spectrum which aggravate course and prognosis of main disease. The article considers issues related to detection of comorbide emotional disorders in patients with cancer. The diagnostic value of psychometric techniques of evaluation of symptoms of anxiety and depression and data concerning of effectiveness and safety of pharmaceutical agents applied in oncological practice are analyzed. The results of implementation of techniques of psychotherapeutic intervention in complex treatment of patients with oncological pathology are presented. The conclusion is made that further development of actual issues of diagnostic, therapy and prevention of anxiety and depressive conditions in patients with cancer require integration of scientific and practical activities of oncologists, psychiatrists and psychotherapists.

About the authors

I. V Scherbakova

The A.E. Evdokimov Moscow state medical stomatological university

Email: irinash26@mail.ru
доктор мед. наук, профессор кафедры психиатрии и наркологии 127473 Moscow, Russia

L. M Bardenshtein

The A.E. Evdokimov Moscow state medical stomatological university

127473 Moscow, Russia

S. V Averianova

The road clinical hospital on Saratov-II station of JSCo "RZD"

410004 Saratov, Russia

References

  1. Ромасенко В.А., Скворцов К.А. Нервно-психические нарушения при раке. М.; 1961.
  2. Смулевич А.Б., Андрющенко А.В., Бескова Д.А. Психические расстройства в онкологии (результаты мультицентровой программы "Синтез"). Психические расстройства в общей медицине. 2009; 1: 4-11.
  3. Wein S., Sulkes A., Stemmer S. The oncologist s role in managing depression, anxiety, and demoralization with advanced cancer. Cancer J. 2010; 16(5): 493-9.
  4. Pasquini M., Biondi M., Costantini A., Cairoli F., Ferrarese G., Picardi A. et al. Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division. Depress. Anxiety. 2006; 23(7): 441-8.
  5. Onitilo A.A., Nietert P.J., Egede L.E. Effect of depression on allcause mortality i adults with cancer and differential effects by cancer site. Gen. Hosp. Psychiatry. 2006; 28(5): 396-402.
  6. Brintzenhofe-Szoc К.М., Levin Т.Т., Li К., Kissane D.W., Zabora J.R. Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics. 2009; 50(4): 383-91.
  7. Rhondali W., Perceau E., Berthiller J., Saltel P., Trillet-Lenoir V., Tredan O. et al. Frequency of depression among oncology outpatients and association with other symptoms. Support. Care Cancer. 2012; 20(11): 2795-802.
  8. Delgado-Guay M., Parsons H., Li Z., Palmer J., Bruera E. Symptom distress in advanced cancer patients with anxiety and depression in a palliative care setting. Support. Care Cancer. 2009; 17(5): 573-9.
  9. Yu L.S., Chojniak R., Borba M.A., Girao D.S., Lonrenjo M.T. Prevalence of anxiety in patients awaiting diagnostic procedures in an oncology center in Brazil. Psychooncology. 2011; 20(11): 1242-5.
  10. Барденштейн Л.М., Вельшер Л.З., Аверьянова С.В. Психологические особенности больных раком молочной железы как прогностический фактор. Российский медицинский журнал. 2011; 5: 13-7.
  11. Зотов П.Б., Уманский С.М., Ганцев Ш.Х. Суицидальные действия больных злокачественными новообразованиями. Сибирский вестник психиатрии и наркологии. 2005; 2: 99-101.
  12. Laoutidis Z.G., Mathiak K. Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry. 2013; 13: 140-8.
  13. Baillet F. The organization of psycho-oncology. Cancer Radiother. 2002; 6(Suppl 1): 214s-8s.
  14. Breitbart W., Poppito S., Rosenfeld B., Vickers A.J., Li Y., Abbey J. et al. Pilot randomized controlled trial of individual meaning-centered psychotherapy for patients with advanced cancer. J. Clin. Oncol. 2012; 30(12): 1304-9.
  15. Akizuki N. The role of psycho-oncology in cancer care in Japan. Seishin Shinkeigaku Zasshi. 2010; 112(12): 1210-5.
  16. Travado L., Grassi L., Gil F., Ventura C., Martins C. Southern European Psycho-Oncology Study Group. Physician-patient communication among Southern European cancer physicians: the influence of psychosocial orientation and burnout. Psychooncology. 2005; 14: 661-70.
  17. Passik S.D., Dugan W., McDonald M.V., Rosenfeld B., Theobald D.E., Edgerton S. Oncologists' recognition of depression in their patients with cancer. J. Clin. Oncol. 1998; 16(4): 1594-600.
  18. Patrick D.L., Ferketich S.L., Frame P.S., Harris J.J., Hendricks C.B., Levin B. et al. National Institutes of Health State-of-the-Science Panel. Management in Cancer: Pain, Depression, and Fatigue. J. Natl. Cancer Inst. 2003; 95(15): 1110-7.
  19. Yeh M.L., Chung Y.C., Hsu M.Y., Hsu C.C. Quantifying psychological distress among cancer patients in interventions and scales: a systematic review. Curr. Pain Headache Rep. 2014; 8(3): 399.
  20. Vodermaier A., Linden W., Siu C. Screening for emotional distress in cancer patients: a systematic review of assessment instruments. J. Natl. Cancer Inst. 2009; 101(21): 1464-88.
  21. Mitchell A.J. Short screening tools for cancer-related distress: a review and diagnostic validity meta-analysis. J. Natl. Compr. Canc. Netw. 2010; 8(4): 487-94.
  22. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983; 67(6): 361-70.
  23. Mackenzie L.J., Carey M.L., Sanson-Fisher R.W., D'Este C.A., Paul C.L., Yoong S.L. Agreement between HADS classifications and single-item screening questions for anxiety and depression: a cross-sectional survey of cancer patients. Ann. Oncol. 2014; 25(4): 889-95.
  24. Quill T.E., Arnold R.M., Platt F. "I wish things were different": expressing wishes in response to loss, futility, and unrealistic hopes. Ann. Intern. Med. 2001; 135: 551-5.
  25. Husson O., Mols F., van de Poll-Franse L.V. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Ann. Oncol. 2011; 22(4): 761-72.
  26. Caruso R., Grass L., Nanni M.G., Riba M. et al. Psychopharmacology in psychooncology. Сurr. Psychiatry Rep. 2013; 15(9): 393.
  27. Hardly J.R., O'Shea A., White C., Gilshenan K., Welch L., Douglas C. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. J. Pain Symptom Manage. 2010; 40(1): 111-6.
  28. Vig S., Seibert L., Green M.R. Olanzapine is effective for refractory chemotherapyinduced nausea and vomiting irrespective of chemotherapy emetogenicity. J. Cancer Res. Clin. Oncol. 2014; 140(1): 77-82.
  29. Razavi D., Delvaux N., Farvacques C., De Brier F., Van Heer C., Kaufman L. et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J. Clin. Oncol. 1993; 11(7): 1384-90.
  30. Malik I.A., Khan W.A., Qazilbash М., Ata E., Butt A., Khan M.A. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am. J. Clin. Oncol. 1995; 18(2): 170-5.
  31. Holland J.C., Romano S.J., Heiligenstein J.H., Tepner R.G., Wilson M.G. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology. 1998; 13: 291-300.
  32. Larid B., Colvin L., Fallon M. Management of cancer pain: basic principles and neuropathic cancer pain. Eur. J. Cancer. 2008; 44(8): 1078-82.
  33. Saarto T., Wiffen P.J. Antidepressants for neuropathic pain. Cochrane Database Syst. Rev. 2007; 17(4): CD005454.
  34. Amr Y.M., Yousef A.A. Evaluation of efficacy of the perioperative administration of Venlafaxine or gabapentin on acute and chronic postmastectomy pain. Clin J. Pain. 2010; 26(5): 381-5.
  35. Rodriguez Vega S., Palao A., Torres G., Hospital A., Benito G., Perez E. et al. Combined therapy versus usual care for the treatment of depression in oncologic patients: a randomized controlled trial. Psychooncology. 2011; 20(9): 943-52.
  36. Arimochi H., Morita K. Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. Eur. J. Pharmacol. 2006; 541(1-2): 17-23.
  37. Jahchcm N.S., Dudley J.T, Mazur Р.К., Flores N., Yang D., Palmerton A. et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lungcancer and other neuroendocrine tumors. Cancer Discov. 2013; 3(12): 1364-77.
  38. Higgins S.C., Pilkington G.J. The in vitro effects of tricyclic drugs and dexamethasone on cellular respiration of malignant glioma. Anticancer Res. 2010; 30(2): 391-7.
  39. Gil-Ad I., Zolokov A., Lomnitski L., Taler M., Bar М., Luria D. et al. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice. Int. J. Oncol. 2008; 33(2): 277-86.
  40. Ng C.G., Boks M.P., Zainal N.Z., de Wit N.J. The prevalence and pharmacotherapy of depression in cancer patients. J. Affect. Disord. 2011; 131(1-3): 1-7.
  41. Самушия М.А., Мустафина Е.А. Нозогении (психогенные реакции) у женщин со злокачественными опухолями органов репродуктивной системы. Психические расстройства в общей медицине. 2007; 2(3): 11-6.
  42. Резник А.М., Миронычев Г.Н., Арбузов А.Л., Дзюба К.В., Назаралиева А.А. Применение ципрамила при депрессии у больных с онкологическими заболеваниями желудочно-кишечного тракта. Журнал неврологии и психиатрии им. С.С. Корсакова. 2004; 104(9): 39-42.
  43. Musselmatin D.L., Somerset W.I., Guo Y., Manatunga A.K., Porter М., Penna S. et al. A double-blind multicenter parallel-group study of paroxetine, desipramine or placebo in breast cancer patients (stages I, II, III, IV) with major depression. J. Clin. Psychiatry. 2006; 13: 288-96.
  44. Costa D., Mogos I., Toma T. Efficacy of mianserin in the treatment of depression of women with cancer. Acta Psychiatr. Scand. 1985; 13(suppl. 320): 85-92.
  45. van Heeringen K., Zivkov M. Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. Br. J. Psychiatry. 1996; 169(4): 440-3.
  46. Razavi D., Allilaire J.F., Smith М., Salimpour A., Verra М., Desclaux B. et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr. Scand. 1996; 13: 205-10.
  47. Fisch M.J., Loehrer P.J., Kristeller J., Passik S., Jung S.H., Shen J. et al. Oncology Group Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J. Clin. Oncol. 2003; 21(10): 1937-43.
  48. Navari R.M., Brenner M.C., Wilson M.N. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res. Treat. 2008; 13: 197-201.
  49. Fisch M. Treatment of depression in cancer. J. Natl. Cancer Inst. Monogr. 2004; (32): 105-11.
  50. Evans R.L., Connis R.T. Comparison of brief group therapies for depressed patients receiving radiation treatment. Public Health Rep. 1995; 110(3): 306-11.
  51. Kuijer R.G., Buunk B.P., De Jong G.M., Ybema J.F., Sanderman R. Effects of a brief intervention program for patients with cancerand their partners on feelings of inequity, relationship quality and psychological distress. Psychooncology. 2004; 13(5): 321-34.
  52. Akechi T., Okuyama T., Onishi J., Morita Т., Furukawa T. A. Psychotherapy for depression among incurable cancer patients. Cochrane Database Syst. Rev. 2008; Issue 2: CD005537.
  53. Jakuhovits E. Possibilities of hypnosis and hypnosuggestive methods in oncology. Magy. Onkol. 2011; 55(1): 22-31.
  54. Spiegel D., Bloom J.K., Kraemer H.C., Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989; 2: 888-91.
  55. Kuchler Т., Bestmann B., Rappat S., Henne-Bnms P., Wood-Pauphinee S. Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial. J. Clin. Oncol. 2007; 25(19): 2702-8.
  56. Бажин Е.Ф., Гнездилов А.В. Психофармакологические и психокоррекционные аспекты реабилитации онкологических больных. Журнал клинической психоонкологии. 2003; 3: 18-23.
  57. Pothoulaki M., MacDonald R., Flowers P. An interpretative phenomenological analysis of an improvisational music therapy program for cancer patients. J. Music Ther. 2012; 49(1): 45-67.
  58. Bradt J., Dileo C., Grocke D., Magill L. Music interventions for improving psychological and physical outcomes in cancer patients. Cochrane Database Sys. Rev. 2011; 10(8): CD006911.
  59. Kovacs Z., Szabo C., Fulop E. The therapy helps - psychosocial support of patients diagnosed with breast-cancer; reducing anxiety and depression. Psychiat. Hung. 2013; 28(4): 454-63.
  60. Keller M.B., McCullough J.P., Klein D.N., Arnow B., Dunner D.L., Gelenberg A.J. et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N. Engl. J. Med. 2000; 342: 1462-70.

Copyright (c) 2015 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies